{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:12:17Z","timestamp":1789661537725,"version":"4.0.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600455"],"award-info":[{"award-number":["81600455"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Non-alcoholic steatohepatitis (NASH) is a chronic liver disease histologically characterized by liver steatosis, hepatocellular injury, inflammation and fibrosis, resulting in cirrhosis and hepatocellular carcinoma, but effective measures and obvious pathogenesis for NASH remain elusive. Chrysin (CH) has been reported to have anti-inflammatory effects but shows lower bioavailability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this study, a chrysin nanoliposome (CH-NL) was first prepared and characterized. Then, we used the methionine\u2013choline-deficient (MCD) diet to induce a mouse model of NASH. Finally, the effects of CH and CH-NL on NASH were evaluated in the liver of NASH mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>The results showed that CH or CH-NL significantly reduced the accumulation of lipids in hepatocytes, alleviated liver injury, decreased the generation of radical oxygen species, and attenuated the accumulation of collagen fibre in the liver of NASH mice. In addition, CH and its nano-liposomes markedly inhibited the production of inflammatory cytokines and inflammatory cell infiltration in the liver of NASH mice. Further studies found that CH-NL and CH-NL downregulated the MCD diet-induced activation of Toll-like receptor 4 (TLR4) signalling pathway in the liver of mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CH and its nanoliposome alleviated MCD diet-induced NASH in mice, which might be through inhibiting TLR4 signalling pathway.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpp\/rgad031","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T06:43:30Z","timestamp":1681627410000},"page":"1046-1057","source":"Crossref","is-referenced-by-count":13,"title":["Chrysin and its nanoliposome ameliorated non-alcoholic steatohepatitis via inhibiting TLR4 signalling pathway"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1835-6430","authenticated-orcid":false,"given":"Hao","family":"Liu","sequence":"first","affiliation":[{"name":"Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Department of Pharmacology, Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningman","family":"Jiang","sequence":"additional","affiliation":[{"name":"Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Department of Pharmacology, Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Kuang","sequence":"additional","affiliation":[{"name":"Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Department of Pharmacology, Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hu","sequence":"additional","affiliation":[{"name":"Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Department of Pharmacology, Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[{"name":"Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Department of Pharmacology, Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Institute of surgery Research, Daping Hospital, Army Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xinqiao Hospital, Army Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Wan","sequence":"additional","affiliation":[{"name":"Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Department of Pharmacology, Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"2024103012242555400_CIT0001","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.redox.2018.07.011","article-title":"Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: the role of the ERK-CREB pathway and Bnip3-mediated mitophagy","volume":"18","author":"Li","year":"2018","journal-title":"Redox Biol"},{"key":"2024103012242555400_CIT0002","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease \u2013 a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"2024103012242555400_CIT0003","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024103012242555400_CIT0004","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"2024103012242555400_CIT0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol"},{"key":"2024103012242555400_CIT0006","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"2024103012242555400_CIT0007","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2017.10.015","article-title":"Pharmacotherapy for NASH: current and emerging","volume":"68","author":"Konerman","year":"2018","journal-title":"J Hepatol"},{"key":"2024103012242555400_CIT0008","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol"},{"key":"2024103012242555400_CIT0009","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nrd.2015.3","article-title":"Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies","volume":"15","author":"Musso","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"2024103012242555400_CIT0010","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat Rev. Gastroenterol Hepatol"},{"key":"2024103012242555400_CIT0011","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2022.09.020","article-title":"Mitochondrial alterations in fatty liver diseases","volume":"78","author":"Fromenty","year":"2023","journal-title":"J Hepatol"},{"key":"2024103012242555400_CIT0012","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"2024103012242555400_CIT0013","doi-asserted-by":"crossref","first-page":"G270","DOI":"10.1152\/ajpgi.00304.2014","article-title":"Hepatic TLR4 signaling in obese NAFLD","volume":"309","author":"Sharifnia","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2024103012242555400_CIT0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/jgh.12019","article-title":"Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis","volume":"28","author":"Roh","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"2024103012242555400_CIT0015","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/liv.12315","article-title":"Toll-like receptors and liver disease","volume":"34","author":"Kesar","year":"2014","journal-title":"Liver Int"},{"key":"2024103012242555400_CIT0016","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"2024103012242555400_CIT0017","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cyto.2008.01.006","article-title":"LPS\/TLR4 signal transduction pathway","volume":"42","author":"Lu","year":"2008","journal-title":"Cytokine"},{"key":"2024103012242555400_CIT0018","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/10408398.2014.952399","article-title":"The potential of flavonoids in the treatment of non-alcoholic fatty liver disease","volume":"57","author":"Van De Wier","year":"2017","journal-title":"Crit Rev Food Sci Nutr"},{"key":"2024103012242555400_CIT0019","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2174\/0929867322666150805094940","article-title":"Flavonoids and related compounds in non-alcoholic fatty liver disease therapy","volume":"22","author":"Pisonero-Vaquero","year":"2015","journal-title":"Curr Med Chem"},{"key":"2024103012242555400_CIT0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.phytochem.2017.09.016","article-title":"Chrysin: sources, beneficial pharmacological activities, and molecular mechanism of action","volume":"145","author":"Mani","year":"2018","journal-title":"Phytochemistry"},{"key":"2024103012242555400_CIT0021","doi-asserted-by":"crossref","first-page":"116797","DOI":"10.1016\/j.lfs.2019.116797","article-title":"Chrysin: pharmacological and therapeutic properties","volume":"235","author":"Naz","year":"2019","journal-title":"Life Sci"},{"key":"2024103012242555400_CIT0022","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.biopha.2017.06.003","article-title":"An overview on immunoregulatory and anti-inflammatory properties of chrysin and flavonoids substances","volume":"92","author":"Zeinali","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2024103012242555400_CIT0023","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cbi.2015.08.013","article-title":"Chrysin attenuates liver fibrosis and hepatic stellate cell activation through TGF-\u03b2\/Smad signaling pathway","volume":"240","author":"Balta","year":"2015","journal-title":"Chem Biol Interact"},{"key":"2024103012242555400_CIT0024","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bcp.2014.03.016","article-title":"Chrysin attenuates inflammation by regulating M1\/M2 status via activating PPAR\u03b3","volume":"89","author":"Feng","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"2024103012242555400_CIT0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2125.2001.01317.x","article-title":"Disposition and metabolism of the flavonoid chrysin in normal volunteers","volume":"51","author":"Walle","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012242555400_CIT0026","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3390\/pharmaceutics11080370","article-title":"Pharmacokinetics of B-ring unsubstituted flavones","volume":"11","author":"Ancuceanu","year":"2019","journal-title":"Pharmaceutics"},{"key":"2024103012242555400_CIT0027","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1080\/02652048.2018.1559369","article-title":"Development and evaluation of chrysin-phospholipid complex loaded solid lipid nanoparticles \u2013 storage stability and in vitro anti-cancer activity","volume":"35","author":"Komath","year":"2018","journal-title":"J Microencapsul"},{"key":"2024103012242555400_CIT0028","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bcp.2006.12.028","article-title":"Cancer chemopreventive properties of orally bioavailable flavonoids\u2013methylated versus unmethylated flavones","volume":"73","author":"Walle","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"2024103012242555400_CIT0029","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/21691401.2018.1434661","article-title":"Nanoscale modification of chrysin for improved of therapeutic efficiency and cytotoxicity","volume":"46","author":"Sulaiman","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"2024103012242555400_CIT0030","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ejpb.2014.03.011","article-title":"Nanoparticles generated by PEG-chrysin conjugates for efficient anticancer drug delivery","volume":"87","author":"Zheng","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012242555400_CIT0031","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/21691401.2017.1282496","article-title":"Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications","volume":"45","author":"Panahi","year":"2017","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"2024103012242555400_CIT0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/bpb.b16-00624","article-title":"Liposomal delivery systems: design optimization and current applications","volume":"40","author":"Abu Lila","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"2024103012242555400_CIT0033","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1248\/bpb.b16-00857","article-title":"Innovations in liposomal DDS technology and its application for the treatment of various diseases","volume":"40","author":"Oku","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"2024103012242555400_CIT0034","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejpb.2013.01.001","article-title":"Nanotoxicological classification system (NCS) \u2013 a guide for the risk-benefit assessment of nanoparticulate drug delivery systems","volume":"84","author":"Keck","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012242555400_CIT0035","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2147\/IJN.S96862","article-title":"Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo","volume":"11","author":"Liu","year":"2016","journal-title":"Int J Nanomedicine"},{"key":"2024103012242555400_CIT0036","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejpb.2016.03.031","article-title":"A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B","volume":"103","author":"Uhl","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012242555400_CIT0037","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijbiomac.2016.03.056","article-title":"Nano-encapsulation of capsaicin on lipid vesicle and evaluation of their hepatocellular protective effect","volume":"88","author":"Giri","year":"2016","journal-title":"Int J Biol Macromol"},{"key":"2024103012242555400_CIT0038","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.biopha.2016.04.033","article-title":"Targeted nano-delivery of novel omega-3 conjugate against hepatocellular carcinoma: regulating COX-2\/bcl-2 expression in an animal model","volume":"81","author":"Khan","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"2024103012242555400_CIT0039","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bbalip.2019.02.003","article-title":"iPla2\u03b2 deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes","volume":"1864","author":"Zhu","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2024103012242555400_CIT0040","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41423-018-0032-0","article-title":"Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice","volume":"16","author":"Du","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"2024103012242555400_CIT0041","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jhep.2006.08.025","article-title":"NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis","volume":"46","author":"dela Pe\u00f1a","year":"2007","journal-title":"J Hepatol"},{"key":"2024103012242555400_CIT0042","doi-asserted-by":"crossref","first-page":"5413461","DOI":"10.1155\/2019\/5413461","article-title":"Animal models of steatosis (NAFLD) and steatohepatitis (NASH) exhibit hepatic lobe-specific gelatinases activity and oxidative stress","volume":"2019","author":"Palladini","year":"2019","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2024103012242555400_CIT0043","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0300060519833527","article-title":"Pathogenesis of and major animal models used for nonalcoholic fatty liver disease","volume":"47","author":"Jiang","year":"2019","journal-title":"J Int Med Res"},{"key":"2024103012242555400_CIT0044","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","article-title":"Innate immunity and inflammation in NAFLD\/NASH","volume":"61","author":"Arrese","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2024103012242555400_CIT0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for chemokines in liver disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"key":"2024103012242555400_CIT0046","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/cmi.2014.2","article-title":"The role of neutrophils in the development of liver diseases","volume":"11","author":"Xu","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"2024103012242555400_CIT0047","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.redox.2015.08.015","article-title":"Redox-fibrosis: impact of TGF\u03b21 on ROS generators, mediators and functional consequences","volume":"6","author":"Richter","year":"2015","journal-title":"Redox Biol"},{"key":"2024103012242555400_CIT0048","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"2024103012242555400_CIT0049","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024103012242555400_CIT0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024103012242555400_CIT0051","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.5275","article-title":"Bone marrow-derived macrophage contributes to fibrosing steatohepatitis through activating hepatic stellate cells","volume":"248","author":"Han","year":"2019","journal-title":"J Pathol"},{"key":"2024103012242555400_CIT0052","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbi.2018.11.021","article-title":"Protective role of chrysin on thioacetamide-induced hepatic encephalopathy in rats","volume":"299","author":"El-Marasy","year":"2019","journal-title":"Chem Biol Interact"},{"key":"2024103012242555400_CIT0053","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.bcp.2009.01.009","article-title":"Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin","volume":"77","author":"Lee","year":"2009","journal-title":"Biochem Pharmacol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/75\/8\/1046\/60220458\/rgad031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/75\/8\/1046\/60220458\/rgad031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:22:19Z","timestamp":1730308939000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/75\/8\/1046\/7123526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgad031","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,8,1]]}}}